Item 1.01 Entry into a Material Definitive Agreement

On March 30, 2020, the Company entered into distribution agreements with Co-Diagnostics Inc. pursuant to which Co-Diagnostics granted the Company the exclusive distribution rights to its qPCR infectious disease kits, Logix Smart COVID-19 PCR diagnostic test and Co-Dx Box™ instrument for Afghanistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. The products covered by this agreement are in vitro diagnostic tests, and Co-Diagnostics has reported in its SEC filings that it has received ISO 13485 certification relating to the design and manufacture of its medical device products, and that the ISO certification indicates that it meets the standards required to self-certify certain of its products and affix a CE marking for sales of its products in countries accepting the CE marking with only minimal further governmental approvals in each country, and its Zika and tuberculosis tests were CE-marked in 2018, its first multiplex test (Zika, Dengue, and Chikungunya) was CE-marked in 2019, and it received a CE mark for its Logix Smart Covid-19 test for corona virus in February 2020.

The distribution agreement has a term of one year, but can be terminated by either party on 30 days' notice. The agreement provide that it is the Company's responsibility to obtain all necessary licenses and permits for the marketing of the product in the countries covered by the agreement. The Company does not have any offices or facilities in Afghanistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan or Uzbekistan and intends to distribute the products through sub-distributors or other representatives.

Item 7.01 Regulation FD Disclosure

On March 30, 2020, the Company issued a press release covering the Afghanistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan distribution agreement.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



  99.1     Distribution agreement dated March 19, 2020 between the Company and
         Co-Diagnostics Inc. for Afghanistan, Kazakhstan, Kyrgyzstan, Tajikistan,
         Turkmenistan, and Uzbekistan *

  99.2     Press release dated March 30, 2019


_________

* Confidential information in this agreement has been omitted.






2

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 31, 2020 PreCheck Health Services, Inc.



                     By:  /s/ Justin E. Anderson
                          Justin E. Anderson
                          Chief Executive Officer





3

© Edgar Online, source Glimpses